<div id="readability-page-1"><p>In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Vyome Holdings, with a price target of <span id="expert-recommendation-target">$15.00</span>.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Jason McCarthy has given his Buy rating due to a combination of factors tied to Vyome’s lead program and financial position. He highlights that VT-1953, a topical gel for malignant fungating wounds, has generated robust Phase 2 data showing statistically significant improvement in malodor, pain, and quality of life versus vehicle, with no treatment-related safety issues, which strengthens the case for the drug’s clinical profile.</p> <p>He also notes that the company is preparing to initiate a pivotal Phase 3 trial in a rare, severely underserved indication that currently lacks approved therapies, implying a sizable commercial opportunity exceeding $2B. In addition, Vyome’s existing cash balance, supplemented by available ATM capacity, appears sufficient to fund operations into mid-2027 and advance VT-1953 through key inflection points, leading him to view the shares as undervalued relative to the program’s de-risked outlook and upcoming catalysts.</p> <p>McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Moleculin Biotech, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of <span>-14.2%</span> and a 32.73% success rate on recommended stocks.</p> </div>

HIND

SBIO

LABU

<p>Jason McCarthy from Maxim Group has maintained a Buy rating on Vyome Holdings with a price target of $15.00. He cites strong Phase 2 data for VT-1953, a topical gel for malignant fungating wounds, and the upcoming pivotal Phase 3 trial as key factors. The drug addresses a significant market opportunity exceeding $2B, and Vyome's financial position supports operations into mid-2027. McCarthy views the shares as undervalued given the program's de-risked outlook and upcoming catalysts.</p>

Tip Ranks

Vyome

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Aprea Therapeutics

Moleculin Biotech

Plus Therapeutics

Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market